EMA/PE/0000240469

Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: EMA/PE/0000240232

Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine hydrochloride,dolutegravir sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000240971

Human medicines European public assessment report (EPAR): Telmisartan Actavis, telmisartan, Date of authorisation: 29/09/2010, Revision: 16, Status: Authorised

EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia, Online, from 30 June 2026, 14:00 (CEST) to 30 June 2026, 18:00 (CEST)

EMA fast tracks review of a medicine for metastatic pancreatic cancer

Opinion/decision on a Paediatric investigation plan (PIP): Kapruvia, Difelikefalin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000237641

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia, finerenone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiac disorders, PIP number: EMA/PE/0000241538

PCWP/HCPWP joint meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 June 2026, 09:15 (CEST) to 1 July 2026, 12:00 (CEST)

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Bucharest, Romania, from 26 October 2026 to 28 October 2026